摘要
目的观察健脾利湿中药对复发性外阴阴道假丝酵母菌病(RVVC)的阴道局部免疫功能的影响。方法将50例RVVC患者随机分为中西医结合治疗组(治疗组)和对照组,两组患者均根据敏感药物进行强化治疗及巩固治疗,疗程共3个月,治疗组根据辨证以完带汤加减同治,分别观察两组对阴道局部免疫因子的影响。结果 50例中共有39例完成随访,其中治疗组21例、对照组18例,随访率为78%。治疗组患者治疗后阴道灌洗液IFN-γ水平明显下降,与治疗前比较,差异有显著性意义(P<0.05),IL-4水平治疗前后比较差异有显著性意义(P<0.05)。对照组患者治疗前后阴道灌洗液IFN-γ及IL-4水平比较差异无显著性意义(P<0.05)。结论健脾利湿方药能显著改善复发性外阴阴道假丝酵母菌病(RVVC)的细胞免疫功能,降低RVVC复发率及延长复发时间,从而提高RVVC的远期疗效。
Objective to observe the spleen of TCM with dampness to recurrent vulva vagina candida disease（RVVC） of vaginal local immune function. Methods 50 cases of RVVC patients were randomly divided into thecooperation of Chinese and western medicine treatment group （treatment group） and control group, two groups ofpatients were based on the sensitive drugs for intensive therapy and consolidation therapy, treatment, a total of 3months, based on syndrome differentiation treatment group to finish with tonga subtraction word, respectively toobserve the effects of two groups of vaginal local immune factors. Results there are 39 patients underwentfollow-up in 50 cases, including 21 cases of treatment group and 18 cases of control group, the follow-up ratewas 78 % . Treatment group after treatment in patients with vaginal lavage IFN-gamma levels significantlydecreased, compared with before treatment, significant differences （P〈0.05）, the level of IL-4 significantcomparative differences before and after treatment （P〈0.05）. The control group before and after treatment inpatients with vaginal lavage IFN-gamma and IL-4 level there was no significant difference comparedsignificance （P〉0.05）. Conclusion the spleen can significantly improve the formulas with dampness recurrentvulva vagina candida disease （RVVC） cellular immune function, reduce the recurrence of RVVC recurrence rateand prolong time, thus improve the long-term curative effect of RVVC.
出处
《佛山科学技术学院学报（自然科学版）》
CAS
2016年第5期76-80,共5页
Journal of Foshan University(Natural Science Edition)
关键词
复发性外阴阴道假丝酵母菌病
健脾利湿
阴道免疫因子
recurrent genital vaginal candida disease
invigorating spleen to remove dampness
vaginal immunefactors
